Skip to main navigation Skip to search Skip to main content

Covid-19 public health road map: Opioid substitution treatment (OST) adherence

  • Hannah E Family*
  • , Angel Chater
  • , Myles-Jay Linton
  • , Neil Howlett
  • , Rosalind Gittins
  • , Lindsey A Hines
  • , Jenny Scott
  • , Elizabeth Jenkinson
  • , Vivien Swanson
  • , Tracy Epton
  • , Nicky Knowles
  • , Shanara Abdin
  • , Jo Hart
  • , Atiya Kamal
  • , Lucie Byrne-Davis
  • , Chris Armitage
  • , Madelynne Arden
  • , Ellie Whittaker
  • , Paul Chadwick
  • , Lesley Lewis
  • Daryl O'Connor, John Drury, Emily McBride, Gillian Shorter
*Corresponding author for this work

Research output: Book/ReportCommissioned report

Abstract

Behavioural Science Recommendations
Adhering to opioids prescribed as part of OST can benefit both physical and psychological health. OST adherence of those prescribed is influenced by what they know and what they can do (capability); people around them and the physical environment (opportunity); and by beliefs, what they want, how they see themselves, how they regulate emotion, and habit (motivation).

To support changes since COVID-19:
• Facilitate the planning and development of OST services, which enable individuals to receive support and timely access to OST3-7, and offer assertive outreach and virtual consultations where appropriate,
• Continue to liberalise OST dispensing arrangements where appropriate, guided by an individuals' risk assessment which includes risk of diversion, safeguarding, and safe storage arrangements. Providers must communicate effectively with the individual and collaborate on proposed changes to dispensing arrangements to support adherence,
• Where needed, adjust services to facilitate physical-distancing, self-isolating, quality of life, and shielding (if relevant); this may include dispensing larger volumes for self-administration at home, delivery of medication, long-acting formulations, and/or identification of a nominated individual to assist in the collection, management, or safe storage of prescriptions. Support access to digital devices for those receiving mobile or online support,
• Vaccine uptake (including hepatitis B and COVID-19 vaccines) to be encouraged and facilitated8-9,
• Continue harm reduction interventions, holistic, and wrap-around support services10 such as take-home naloxone and needle syringe provision; blood borne virus screening and treatment; psychosocial interventions (including digital and virtual options); advice on self-care, health, and wellbeing; and services to facilitate housing and safe shelter for those who are homeless or vulnerably housed11, or otherwise at risk.

We recommend following the British Psychological Society's Behavioural Science and Disease Prevention: Psychological guidance12 to shape any policy and communications strategy.
Original languageEnglish
Place of PublicationLeicester
PublisherBritish Psychological Society
Number of pages10
Publication statusPublished - 19 Aug 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Covid-19 public health road map: Opioid substitution treatment (OST) adherence'. Together they form a unique fingerprint.

Cite this